Avalon Pharmaceuticals: AVN944 Biomarkers Correlate with Clinical Effects and Disease Stabilization in Adult AML Patients

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced preliminary results from its ongoing AVN944 Phase I trial in adult Acute Myelogenous Leukemia (AML) patients at the American Society of Hematology (ASH) Annual Meeting.